Multiple Myeloma Epidemiology

Key Highlights

• In 2022, there were more than 70,000 incident cases of multiple myeloma in the 7MM, which is expected to rise by 2034, and the United States had the highest among seven major markets.
• Germany had the highest number of incident cases of multiple myeloma among the EU4 and the UK, followed by France, whereas Spain had the lowest number of cases.
• When it comes to age-specific cases of multiple myeloma, the age group of 65 and above years has the highest number of cases accounting for nearly 70% of cases in the United States, followed by 55–64 and 0–54 years.
• In the 7MM, among the treated patient pool, the maximum patients were under the frontline transplant ineligible pool, followed by second-line accounting for approximately 47,000 and 40,000, respectively, and the least patients were observed in the frontline transplant eligible group in 2022.

DelveInsight’s “Multiple Myeloma (MM) – Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of multiple myeloma, historical and forecasted epidemiology as well as multiple myeloma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The multiple myeloma market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM multiple myeloma market size from 2021 to 2034. The report also covers current multiple myeloma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Multiple Myeloma Disease Understanding and Treatment Algorithm

Multiple Myeloma Overview

Multiple myeloma (MM) is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from accumulating terminally differentiated monoclonal plasma cells (PC) in the bone marrow. Multiple myeloma is a malignant disorder characterized by uncontrolled proliferation of clonal plasma cells, causing various complications leading to organ dysfunction and eventually death. Recently, there has been a change in the pathogenesis of myeloma leading to major improvements in managing patients with multiple myeloma. A significant contributor to treatment failure leading to clinical relapse is the emergence of multidrug resistance (MDR), a phenomenon whereby the cancer cells resist various structurally and functionally unrelated drugs following exposure to a single chemotherapeutic agent.

Multiple Myeloma Diagnosis

Multiple myeloma is often diagnosed based on tests, the patient’s symptoms, including bone pain, weakness, hypercalcemia, etc., and the doctor’s physical exam. Following these symptoms, lab tests are conducted, mainly blood and urine tests. After these tests are done, a biopsy is conducted (bone marrow aspiration, fine needle aspiration). Apart from these tests, a few other tests are also used to confirm the diagnosis of multiple myeloma, namely plasma cell proliferation, which shows what percentage of plasma cells are dividing; serum viscosity which measures the thickness of the blood; echocardiogram, an ultrasound that checks how well the heart is beating and pumping blood. After the diagnosis is done, it is also important to check whether it is smoldering myeloma or active myeloma, depending on this, treatment is initiated.

Further details related to diagnosis are provided in the report…

Multiple Myeloma Epidemiology

The multiple myeloma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of multiple myeloma, total symptomatic cases of multiple myeloma, gender-specific cases of multiple myeloma, age-specific cases of multiple myeloma, transplant eligible cases of multiple myeloma, and treated patient pool across all lines of therapies in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2021 to 2034. The total incident cases of multiple myeloma in the 7MM comprised more than 70,000 cases in 2022 and are projected to increase during the forecast period (2025-2034).

• In the 7MM, the highest incident cases of MM were seen in the United States, followed by EU4 and the UK in 2022.
• Among the EU4 countries, Germany accounted for the highest number of incident multiple myeloma cases, whereas Spain accounted for the lowest cases in 2022.
• Multiple myeloma is more common in males as compared to females. In the United States, more than 50% of males are diagnosed with multiple myeloma.
• In the 7MM, there were around 47,000 frontline transplant-ineligible patients and nearly 17,000 frontline transplant-eligible patients of multiple myeloma in 2022.
• When it comes to age-specific cases of Multiple myeloma, the age group of 65 and above years has the highest number of cases accounting for more than 70% of cases in the United States, followed by 55–64 and 0–54 years.
• In the United States, approximately 70% of multiple myeloma patients come under the age group of 65 and above years.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on multiple myeloma evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including oncologists, radiation oncologists, surgical oncologists, and others.

Delveinsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Dana–Farber Cancer Institute, Colorado Blood Cancer Institute, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or multiple myeloma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of multiple myeloma, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.
• A detailed review of the multiple myeloma epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Multiple Myeloma (MM) Report Insights

• Patient Population
• Patient population by gender, stage, and age
• Country-wise Epidemiology Distribution

Multiple Myeloma (MM) Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Multiple Myeloma Epidemiology Segmentation

Multiple Myeloma (MM) Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions

Epidemiology Insights:

• What are the disease risk and burdens and of multiple myeloma? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to multiple myeloma?
• What is the historical and forecasted multiple myeloma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which age group is the largest contributor in patients affected with multiple myeloma?
• What factors affect the increase in the patient number in later lines of multiple myeloma therapy?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Related Articles By DelveInsight On Multiple Myeloma:

• Understanding High Risk Smoldering Multiple Myeloma: A Bridge Between MGUS and Multiple Myeloma
• The changing landscape of Multiple Myeloma therapies market
• Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse
• CELMoDs – A Worthy Successor to REVLIMID?
• Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
• A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
• Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment
• BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?
• Multiple Myeloma Market: Infographics
• Multiple Myeloma Newsletter